Targeted Therapy in the Management of Modern Craniopharyngiomas

被引:9
作者
Reyes, Maikerly [1 ]
Taghvaei, Mohammad [1 ]
Yu, Siyuan [1 ]
Sathe, Anish [1 ]
Collopy, Sarah [1 ]
Prashant, Giyarpuram N. [1 ]
Evans, James J. [1 ]
Karsy, Michael [2 ]
机构
[1] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA
[2] Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2022年 / 27卷 / 04期
关键词
craniopharyngioma; adamantinomatous; papillary; BRAF; beta-catenin; CTNNB1; immunotherapy; molecular biology; EGFR; TUMOR TRANSFORMING GENE; ADAMANTINOMATOUS CRANIOPHARYNGIOMAS; BETA-CATENIN; PHASE-II; RECURRENT CRANIOPHARYNGIOMAS; INTRATUMORAL CHEMOTHERAPY; CYSTIC CRANIOPHARYNGIOMA; CELL-ADHESION; BRAF; EXPRESSION;
D O I
10.31083/j.fbl2704136
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment. Methods: We undertook a focused review of relevant articles, clinical trials, and molecular summaries regarding CP. Results: Genetic and immunological markers show variable expression in different types of CP. BRAF is implicated in tumorigenesis in papillary CP (pCP), whereas CTNNB1 and EGFR are often overexpressed in adamantinomatous CP (aCP) and VEGF is overexpressed in aCP and recurrent CP. Targeted treatment modalities inhibiting these pathways can shrink or halt progression of CP. In addition, EGFR inhibitors may sensitize tumors to radiation therapy. These drugs show promise in medical management and neoadjuvant therapy for CP. Immunotherapy, including anti-interleukin-6 (IL-6) drugs and interferon treatment, are also effective in managing tumor growth. Ongoing clinical trials in CP are limited but are testing BRAF/MET inhibitors and IL-6 monoclonal antibodies. Conclusions: Genetic and immunological markers show variable expression in different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional clinical trials and targeted therapies will be important to improve CP patient outcomes.
引用
收藏
页数:14
相关论文
共 104 条
  • [1] Roles of fascin in cell adhesion and motility
    Adams, JC
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2004, 16 (05) : 590 - 596
  • [2] Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas
    Agozzino, Lucio
    Ferraraccio, Franca
    Accardo, Marina
    Esposito, Salvatore
    Agozzino, Manuela
    Cuccurullo, Luigi
    [J]. ULTRASTRUCTURAL PATHOLOGY, 2006, 30 (03) : 143 - 150
  • [3] Radiotherapy of Parasellar Tumours
    Albano, Luigi
    Losa, Marco
    Flickinger, John
    Mortini, Pietro
    Minniti, Giuseppe
    [J]. NEUROENDOCRINOLOGY, 2020, 110 (9-10) : 848 - 858
  • [4] Alexandraki K.I., 2021, TOUCHREVIEWS ENDOCRI, V17, P121, DOI [10.17925/EE.2021.17.2.121, DOI 10.17925/EE.2021.17.2.121]
  • [5] The Medical Therapy of Craniopharyngiomas: The Way Ahead
    Alexandraki, Krystallenia, I
    Kaltsas, Gregory A.
    Karavitaki, Niki
    Grossman, Ashley B.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (12) : 5751 - 5764
  • [6] Sox2+ Stem/Progenitor Cells in the Adult Mouse Pituitary Support Organ Homeostasis and Have Tumor-Inducing Potential
    Andoniadou, Cynthia Lilian
    Matsushima, Danielle
    Gharavy, Seyedeh Neda Mousavy
    Signore, Massimo
    Mackintosh, Albert Ian
    Schaeffer, Marie
    Gaston-Massuet, Carles
    Mollard, Patrice
    Jacques, Thomas Stanley
    Le Tissier, Paul
    Dattani, Mehul Tulsidas
    Pevny, Larysa Halyna
    Martinez-Barbera, Juan Pedro
    [J]. CELL STEM CELL, 2013, 13 (04) : 433 - 445
  • [7] Cystic lesions of the sellar-suprasellar region - diagnosis and treatment
    Andrysiak-Mamos, Elzbieta
    Sagan, Karol
    Sagan, Leszek
    Sowinska-Przepiera, Elibieta
    Syrenicz, Anhelli
    [J]. ENDOKRYNOLOGIA POLSKA, 2018, 69 (02) : 212 - 220
  • [8] Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target
    Apps, John R.
    Carreno, Gabriela
    Mario Gonzalez-Meljem, Jose
    Haston, Scott
    Guiho, Romain
    Cooper, Julie E.
    Manshaei, Saba
    Jani, Nital
    Holsken, Annett
    Pettorini, Benedetta
    Beynon, Robert J.
    Simpson, Deborah M.
    Fraser, Helen C.
    Hong, Ying
    Hallang, Shirleen
    Stone, Thomas J.
    Virasami, Alex
    Donson, Andrew M.
    Jones, David
    Aquilina, Kristian
    Spoudeas, Helen
    Joshi, Abhijit R.
    Grundy, Richard
    Storer, Lisa C. D.
    Korbonits, Marta
    Hilton, David A.
    Tossell, Kyoko
    Thavaraj, Selvam
    Ungless, Mark A.
    Gil, Jesus
    Buslei, Rolf
    Hankinson, Todd
    Hargrave, Darren
    Goding, Colin
    Andoniadou, Cynthia L.
    Brogan, Paul
    Jacques, Thomas S.
    Williams, Hywel J.
    Martinez-Barbera, Juan Pedro
    [J]. ACTA NEUROPATHOLOGICA, 2018, 135 (05) : 757 - 777
  • [9] Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
    Ascierto, Paolo A.
    Minor, David
    Ribas, Antoni
    Lebbe, Celeste
    O'Hagan, Anne
    Arya, Niki
    Guckert, Mary
    Schadendorf, Dirk
    Kefford, Richard F.
    Grob, Jean-Jacques
    Hamid, Omid
    Amaravadi, Ravi
    Simeone, Ester
    Wilhelm, Tabea
    Kim, Kevin B.
    Long, Georgina V.
    Martin, Anne-Marie
    Mazumdar, Jolly
    Goodman, Vicki L.
    Trefzer, Uwe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3205 - +
  • [10] Craniopharyngiomas: Challenges and Controversies
    Asha, Mohammed J.
    Oswari, Selfy
    Takami, Hirokazu
    Velasquez, Carlos
    Almeida, Joao Paulo
    Gentili, Fred
    [J]. WORLD NEUROSURGERY, 2020, 142 : 593 - 600